IQVIA (NYSE:IQV) Price Target Lowered to $223.00 at Robert W. Baird

IQVIA (NYSE:IQV) had its price target lowered by Robert W. Baird from $256.00 to $223.00 in a report published on Friday morning, Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

Several other brokerages also recently weighed in on IQV. Barclays decreased their target price on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Royal Bank of Canada assumed coverage on shares of IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective on the stock. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and cut their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Evercore ISI reduced their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $261.24.

IQVIA Stock Performance

NYSE:IQV traded up $3.34 during midday trading on Friday, reaching $209.16. The stock had a trading volume of 1,791,887 shares, compared to its average volume of 1,125,496. The stock has a market capitalization of $38.13 billion, a P/E ratio of 27.45, a PEG ratio of 2.01 and a beta of 1.51. IQVIA has a 1-year low of $181.03 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.85. The firm’s fifty day simple moving average is $234.31 and its 200-day simple moving average is $229.74.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On IQVIA

A number of hedge funds have recently modified their holdings of IQV. Versant Capital Management Inc raised its stake in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new position in shares of IQVIA during the second quarter worth about $27,000. Capital Performance Advisors LLP acquired a new stake in IQVIA in the 3rd quarter valued at approximately $27,000. Park Place Capital Corp bought a new stake in IQVIA in the 3rd quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. acquired a new position in IQVIA during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.